Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in refractory myasthenia gravis
NCT04431895Phase 1Completed
- Sponsor
- Huashan Hospital
- Start
- Jun 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of tofacitinib oral solution in myasthenia gravis (MG), sponsored by Huashan Hospital. Primary endpoint: Quantitative Myasthenia Gravis at 6 months. Started Jun 2020; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04431895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431895.